Related Experiment Video
Updated: Dec 30, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Mutant KRAS at the Heart of Tumor Immune Evasion
Febe van Maldegem1, Julian Downward2
1Oncogene Biology, Francis Crick Institute, London NW1 1AT, UK.
Abstract:
In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.
Insights
Targeted KRAS-G12C inhibition with AMG 510 may enhance cancer immunotherapy. Combining this targeted therapy with immune checkpoint blockade shows promise for potentiating immune rejection in cancer treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Therapeutic combinations for cancer treatment are crucial.
- Targeted inhibitors and immunotherapy pairings are under-explored.
- KRAS mutations are common oncogenic drivers in cancer.
Purpose of the Study:
- To investigate the potential of combining a novel KRAS-G12C inhibitor with immunotherapy.
- To evaluate if AMG 510 can enhance anti-tumor immune responses.
Main Methods:
- Utilized the novel KRAS-G12C inhibitor AMG 510.
- Combined AMG 510 with immune checkpoint blockade therapy.
- Assessed the potentiation of immune rejection.
Main Results:
- The KRAS-G12C inhibitor AMG 510 demonstrated the ability to potentiate immune rejection.
- Combination therapy showed enhanced anti-cancer immune activity.
Conclusions:
- Targeted inhibition of KRAS-G12C with AMG 510 can synergize with immune checkpoint blockade.
- This combination strategy holds potential for improving cancer immunotherapy outcomes.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Related Concept Videos
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Tumor Microenvironment
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
Tumor Immunotherapy